Blog
Viatris Just Snagged a Major FDA Approval
In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment.
Since
2 Top Financial Companies Poised to Trounce the Market
As the market continues to sell off growth stocks that report anything less than perfection during earnings season, it has been particularly eye-catching to see companies post gains after giving an
Wayfair Is Down 60% From Highs -- Time to Buy?
Shares of Wayfair (NYSE: W) are down over 60% after reaching an all-time high of $355.96 in March 2021. Revenue fell 3% last year, coming off a spike in demand in 2020. The deceleration in growth
Is W.P. Carey's Dividend in Trouble?
One of the more diversified real estate investment trusts (REITs) on the scene, W.P. Carey (NYSE: WPC), is at first blush a reliable dividend payer. The company has been making regular shareholder
This Metaverse Stock Could Test Investors' Patience
SPAC stocks became a market phenomenon in 2020 and 2021 when more than 800 of these special purpose acquisition companies went public on the hopes of an eventual merger with another company. Those
Why Dave Shares Took a 65% Dive Last Month
Shares of financial technology company Dave (NASDAQ: DAVE) plunged 65.2% lower in February 2022, according to data from S&P Global Market Intelligence. Having launched through a special-purpose
3 Reasons I Won't Invest Like Warren Buffett
Warren Buffett is pretty much a stock-picking genius and has managed to amass a staggering amount of wealth in his lifetime. As such, he's a pretty good role model when it comes to investing.
But as
Why Stitch Fix's Stock Price Is Falling Ahead of Earnings
Stitch Fix (NASDAQ: SFIX) will report results for its fiscal second quarter on Tuesday, March 8, after the market closes. Wall Street analysts have soured on the stock lately, with the company
The Smartest Dividend Aristocrats to Buy With $500 Right Now
Dividend Aristocrats are an elite group of dividend-paying S&P 500 stocks that have long histories (a minimum of 25 consecutive years) of increasing dividends year after year. Real estate investment
2 Growth Stocks Down 47% to 70% That Wall Street Says Could Soar This Year
The current macroeconomic environment has hit growth investors particularly hard. In fact, the S&P 500 Growth Index has entered correction territory, as it currently sits 14% below its all-time
Would Buying NFL Sunday Ticket Be a Mistake for Apple or Amazon?
The NFL Sunday Ticket package -- broadcasting every out-of-market game to subscribers -- is up for grabs, and Apple (NASDAQ: AAPL) and Amazon (NASDAQ: AMZN) are the leading bidders. The winning
Investing in NFTs? Here's Why You Should Buy Shopify Stock
NFT sales skyrocketed to the moon in 2021. Working from a base of hundreds of millions of dollars in 2020, NFT sales rocketed to $25 billion globally in 2021 as digital artists, musicians, video
How to Retire With $1 Million on a $50,000 Salary
If you're dreaming of a seven-figure retirement nest egg but don't think you'll ever earn enough to get there, think again. A little now can turn into a lot later. The key is consistency, and time
Why You Can't Win in the Stock Market Without Risk
When investing in the stock market, every company has a risk, and it's all about managing that risk to be successful. In this video clip from "The Morning Show" on Motley Fool Live, recorded on Feb
Down 64% in 2022, This No-Brainer Metaverse Stock Can Be Bought for Just $8
Matterport (NASDAQ: MTTR) is a spatial data company that provides software that organizations and individuals use to digitize parts of the physical world to create "digital twins" that can then be
2 Unstoppable Long-Term Trends to Invest In
Cloud computing and cannabis are two high-growth sectors that all investors may want to have some exposure to in the long haul. They possess some of the most promising opportunities out there today.
3 Reasons Autodesk Stock Is a Must-Buy Right Now
In 2011, renowned venture capitalist Marc Andreessen made the claim that "software is eating the world." Over the last 10 years, this vision has been realized, with software and digital tools
2 No-Brainer Stocks to Buy Right Now for Less Than $85
The recent market sell-off has been painful for investors. The S&P 500 is down 8% year to date, and many growth stocks have tumbled even farther. Long-term investors know that market drops are the
2 Monster Stocks to Buy Without Any Hesitation
Realty Income (NYSE: O) and Intuitive Surgical (NASDAQ: ISRG) are two companies that offer dependable returns backed up by their consistent growth. These businesses, though vastly different, offer
1 Overvalued Buffett Stock I Won't Touch
Stocks with high growth potential often come with a matching high premium. These are often justified based on the potential for gains. Many investors are willing to pay for stocks that can bring
3 Reasons To Avoid Dividend-Paying Stocks
Dividend stocks have some appeal for a lot of investors. Companies paying a dividend are usually mature and produce strong enough earnings to cover their payout. A long history of paying a dividend
2 Things You Must Know About Social Security -- Even If Retirement Is Decades Away
If you're in your 20s or 30s, Social Security may not exactly be on your radar. Not only might retirement be many decades away, but you may be more focused on other things -- like paying off
This Beaten-Down Growth Stock Is Still a Buy
I won't sugar-coat it. PayPal (NASDAQ: PYPL) has been one of the worst-performing stocks in the financial sector recently. Shares are down by more than 65% from their mid-2021 all-time high and have
2 Under-the-Radar REITs That Can Set You Up for Life
Real estate investment trusts (REITs) have historically been excellent investments. The sector has a long track record of steadily rising dividends and delivering attractive capital gains. That
Is Intellia a Good Gene-Editing Stock to Buy Now?
The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NASDAQ: NTLA) dazzled the medical community with clinical trial


